BioUtah Life Sciences Delegation Showcases Utah Innovation in Australia

As part of Governor Spencer Cox’s Australia Trade Mission from October 19–25, BioUtah led a focused Life Sciences Track highlighting Utah’s growing global leadership in biotechnology, medtech, diagnostics, and health innovation. The delegation met with prominent Australian partners, investors, and regulators to explore opportunities for collaboration and market expansion. Companies participating in the trade mission […]

Read More

Seek Labs Expands Global Disease Atlas to Include Hemorrhagic Fever Viruses

    Salt Lake City, Utah – October 21, 2025 Salt Lake City-based biotech firm Seek Labs announced today that it has expanded its Global Disease Atlas™ to include several of the world’s deadliest hemorrhagic fever viruses (HFVs) — namely, Ebola virus, Marburg virus, Lassa virus, Hantavirus, Crimean‑Congo hemorrhagic fever virus (CCHFV), and Rift Valley fever virus (RVFV). In July, the company announced that it […]

Read More

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

Posted on

LEHI, Utah, Oct. 23, 2025 /PRNewswire/ — Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational medicine ofirnoflast (HT-6184) for the treatment of Myelodysplastic Syndromes (MDS) — a group […]

Read More

 Journal of Clinical Microbiology Publishes Article on ARUP’s Validation of AI for Parasite Detection 

SALT LAKE CITY, October 21, 2025— ARUP Laboratories today announced the publication of an article in the Journal of Clinical Microbiology describing the company’s validation of a deep convolutional neural network (CNN) to detect parasites in concentrated wet mounts of stool.  For decades, detection of gastrointestinal parasites has relied on traditional microscopy, which is a […]

Read More

SINTX Technologies Receives FDA Clearance for SINAPTIC® Foot & Ankle Implant System

Posted on

SALT LAKE CITY, Utah, Oct. 20, 2025 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramics specializing in biomedical applications of silicon nitride (Si₃N₄), today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the SINAPTIC® Foot & Ankle Osteotomy Wedge System, enabling SINTX’s commercial entry […]

Read More